Webcast and Conference Call to take place on Friday, 27 March 2026 at 15:00 CET / 14:00 GMT / 09:00 AM ETGhent, BELGIUM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Press release Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, today announces that it will publish its annual report and consolidated financial results for the full year of 2025 on Friday, 27 March 2026 at 07:00 CET. Webcast and Conference Call In additi ...

Company Overview - Biotalys NV is an Agricultural Technology (AgTech) company focused on developing precision biocontrol solutions based on proteins for crop protection in both pre- and post-harvest markets [2] - The company utilizes its AGROBODY™ technology platform to create a diverse pipeline of product candidates aimed at addressing key crop pests and diseases, ensuring a favorable safety profile [2] - Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys is headquartered in Ghent, Belgium, and is listed on Euronext Brussels [2] Share Capital and Voting Rights - The total share capital of Biotalys is EUR 5,555,181.05, with a total of 37,568,645 ordinary shares carrying voting rights [3] - The number of rights to subscribe for securities carrying voting rights not yet issued includes 1,779,400 "ESOP Warrants" and 1,504,867 additional "ESOP Warrants" [3] - There are 28,653 share units awarded to independent directors, each obligating the subscription to one new share at an issue price of one EUR per share-unit, with cash settlement options available [3] - The company currently has no outstanding convertible bonds or non-voting shares [3]

Core Insights - Biotalys is progressing with the regulatory approval of its first protein-based biocontrol product, EVOCA, with the U.S. EPA confirming that the scientific review is ongoing and all additional information requests have been addressed [2][3] - The company now anticipates that the final steps of the registration procedure will occur in Q4 2025, a delay from the previous expectation of completion by the end of September [2] - EVOCA is designed to control fungal diseases such as Botrytis and powdery mildew, providing biodegradable solutions for fruit and vegetable growers [3] Company Overview - Biotalys is an AgTech company focused on developing precision biocontrol solutions based on proteins for crop protection in pre- and post-harvest markets [5] - The company utilizes its AGROBODY technology platform to create products that combine the efficacy of traditional chemical solutions with the environmental benefits of biological alternatives [5] - Founded in 2013 as a spin-off from the VIB, Biotalys is headquartered in Ghent, Belgium, and is listed on Euronext Brussels [5]

Core Viewpoint - Biotalys NV has received a transparency notification from Sofinnova Partners SAS regarding its shareholding, indicating that Sofinnova now holds 9.93% of Biotalys' voting rights as of June 11, 2025 [1][2]. Company Information - Biotalys is an Agricultural Technology (AgTech) company focused on developing protein-based biocontrol solutions aimed at sustainable crop protection, providing alternatives to conventional chemical pesticides [5]. - The company utilizes its AGROBODY™ technology platform to create a diverse pipeline of product candidates targeting key crop pests and diseases throughout the agricultural value chain [5]. - Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has been listed on Euronext Brussels since July 2021 and is based in Ghent, Belgium [5]. Shareholding Details - As of June 11, 2025, Sofinnova Partners SAS holds 3,719,820 shares of Biotalys, which corresponds to 9.93% of the total voting rights [2][6]. - The previous notification indicated that Sofinnova held 4,226,962 voting rights, showing a decrease in their holdings [3]. - The threshold crossed by Sofinnova was 10%, with a total denominator of 37,470,062 shares [6].

Core Viewpoint - Biotalys has appointed Luc Van fraeyenhoven as the new Chief Financial Officer (CFO) to lead finance operations as the company advances its product pipeline towards commercialization [2][4]. Company Overview - Biotalys is an Agricultural Technology (AgTech) company focused on developing protein-based biocontrol solutions aimed at providing alternatives to conventional chemical pesticides for sustainable crop protection [5]. - The company utilizes its AGROBODY™ technology platform to create a diverse pipeline of product candidates targeting key crop pests and diseases [5]. - Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has been listed on Euronext Brussels since July 2021 and is based in Ghent, Belgium [5]. Leadership Transition - Luc Van fraeyenhoven, with over three decades of financial experience, will succeed Douglas Minder as CFO [2][3]. - Van fraeyenhoven has held CFO positions in various biotechnology and medtech companies, including Arseus Medical and ActoBio Therapeutics, and has significant experience in finance operations and strategy [3]. - The transition is expected to occur over the next few months, with Van fraeyenhoven expressing eagerness to contribute to Biotalys' innovative technology [2][4]. Strategic Importance - The appointment of Van fraeyenhoven is seen as crucial for Biotalys as it seeks to commercialize its first products while managing resources effectively [4]. - The leadership change is anticipated to enhance financial guidance on both long-term strategies and daily operations [4].